Suven Life Sciences Limited SUVEN.NS · Stock Open Suven Life Sciences Limited in new tab
Suven Life Sciences Limited Analysis (SUVEN.NS)
Is Suven Life Sciences Limited a good investment? Suven Life Sciences Limited (SUVEN.NS) is currently trading at 288.90 INR.
Earnings Schedule: Suven Life Sciences Limited is expected to release its next earnings report on May 11, 2026. The market consensus estimate for Forward EPS is 19.35.
Investor FAQ
Does Suven Life Sciences Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Suven Life Sciences Limited?
Suven Life Sciences Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be May 11, 2026. The company currently has a trailing EPS of -14.89.
Company Profile
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer's disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathic hypersomnia. The company also develops Ropanicant (SUVN-911), an a4ß2 nicotinic acetylcholine receptor (nAChR) antagonist for the treatment of major depressive disorder; Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for management of cognitive dysfunction; and Tenaclidine (SUVN-I6107), a muscarinic M1 positive allosteric modulator for the treatment of cognitive disorders and schizophrenia. In addition, it is involved in the development of programs, such as SUVN-M8036 Serotonin/Dopamine Modulator for psychiatric disorder indications; SUVN-D1044 5-HT4 Agonist for gastrointestinal disorders; M4 PAM for psychosis indications; P2X7 Antagonist for pain and inflammation indications; Multimodal Dual 5-HT2A Antagonist and 5-HT1A Agonist for psychosis and depression indications; 5-HT1A Agonist for treatment resistant depression; Multimodal Dual 5-HT2A Antagonist and SRI for bipolar disorders, and depression and schizophrenia; and M1 PAM for gastrointestinal disorder indications. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
| Year | Total Dividends |
|---|---|
| ▸2019 |
1.50 INR
|
| Feb. 25, 2019 | 1.5000 |
| ▸2018 |
1.50 INR
|
| March 1, 2018 | 1.5000 |
| ▸2017 |
1.00 INR
|
| March 3, 2017 | 1.0000 |
| ▸2016 |
1.00 INR
|
| March 23, 2016 | 1.0000 |
| ▸2015 |
0.60 INR
|
| Sept. 13, 2015 | 0.6000 |
| ▸2014 |
0.46 INR
|
| July 24, 2014 | 0.4607 |
| ▸2013 |
0.30 INR
|
| Sept. 12, 2013 | 0.3000 |
| ▸2012 |
0.30 INR
|
| Oct. 27, 2012 | 0.3000 |
| ▸2011 |
0.25 INR
|
| Sept. 12, 2011 | 0.2500 |
| ▸2010 |
0.25 INR
|
| Aug. 26, 2010 | 0.2500 |
| ▸2009 |
0.25 INR
|
| Oct. 22, 2009 | 0.2500 |
| ▸2008 |
0.25 INR
|
| Oct. 1, 2008 | 0.2500 |
| ▸2007 |
0.25 INR
|
| Nov. 1, 2007 | 0.2500 |
| ▸2006 |
0.46 INR
|
| Oct. 12, 2006 | 0.4606 |
| ▸2005 |
0.46 INR
|
| Sept. 5, 2005 | 0.4606 |
| ▸2004 |
0.46 INR
|
| Sept. 10, 2004 | 0.4606 |
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 15, 2004 | 5:1 |
| March 23, 2007 | 2:1 |
| Oct. 17, 2022 | 1.08 |
Community Discussion